BioXcel Therapeutics, Inc. (BTAI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol BTAI
- Company BioXcel Therapeutics, Inc.
- Price $0.16
- Changes Percentage -11.58
- Change -0.021
- Day Low $0.14
- Day High $0.17
- Year High $5.25
- Year Low $0.74
- Market Cap $24,819,415
- Price Avg 50 EMA (D) $1.01
- Price Avg 200 EMA (D) $1.41
- Exchange NASDAQ
- Volume 1,216,340
- Average Volume 1,016,983
- Open $0.15
- Previous Close $0.18
- EPS -5.75
- PE -0.14
- Earnings Announcement 2026-11-11 05:00:00
- Shares Outstanding $30,877,600
Company brief: BIOXCEL THERAPEUTICS, INC. (BTAI )
- Healthcare
- Biotechnology
- Dr. Vimal D. Mehta Ph.D.
- https://www.bioxceltherapeutics.com
- US
- N/A
- 03-08-2018
- US09075P1057
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.